Pro Life Medica Sp. z o.o.

At Pro Life Medica Sp. z o.o. the ETG Zamość department focuses on Cardiovascular Diseases and related lipid disorders, evaluating new treatments to lower triglyceride levels and mitigate atherosclerotic risk.

• Evaluation of olezarsen for reducing fasting triglycerides
• Study of Hypertriglyceridemia management in patients with atherosclerotic disease
• Assessment of cardiovascular outcomes linked to triglyceride lowering

The site’s investigators are collaborating to advance therapeutic options for heart and vascular health.

Research at the Zamość clinic includes innovative work on Crohn's Disease, aiming to improve endoscopic response through oral medication strategies.

• Efficacy of TAK-279 in moderately to severely active Crohn's disease
• Endoscopic response evaluation at week 12
• Safety and tolerability profiling of the new oral agent

These studies support the development of more effective therapies for inflammatory bowel conditions.

The facility also addresses metabolic lipid abnormalities, such as Hypertriglyceridemia, exploring how targeted interventions can improve overall metabolic health.

• Impact of triglyceride reduction on metabolic risk factors
• Integration of lipid‑lowering therapy with cardiovascular outcome measures
• Investigation of novel antisense approaches for metabolic disease

With a focused team of 19 investigators, the site contributes valuable data to the field of metabolic disease research.